Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi/Regeneron's Sarilumab Faces Stiff Competition Despite Humira Triumph

This article was originally published in Scrip

Executive Summary

Regeneron/Sanofi's IL-6 inhibitor sarilumab has beaten AbbVie's Humira (adalimumab) in a head to head trial. Top line Phase III results show sarilumab more significantly improved the signs and symptoms of rheumatoid arthritis after 24 weeks of treatment than blockbusting Humira did. The data will help differentiate the drug, but competition will remain fierce in the RA space, say analysts.

You may also be interested in...



From Solanezumab To Solithromycin: What To Watch For In Q4

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

R&D Industry Finds Biosimilar Interchangeability Statement By EU Regulators ‘Concerning’

A joint statement from the European Medicines Agency and Heads of Medicines Agencies on biosimilar interchangeability is “concerning,” says Europe’s R&D-based industry federation, EFPIA.

Slovakia Eases Market Access For Innovative Medicines

Slovakia has introduced a new system for agreeing managed entry agreements that will make it easier for companies to get their innovative medicines to the market.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC064721

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel